Likewise, under a multicenter single-arm phase 2 study, designed F-652, a recombinant human IL-22, fused with an immunoglobulin constant region (IgG2-Fc) was noticed for favorable pharmacokinetics (PK) and pharmacodynamic (PD) properties, and was demonstrated as potential treatment for the acute Graft versus host disease (GVHD)-associated dysbiosis in the lower gastrointestinal (GI) tract in combination with systemic corticosteroids [28, 31]. The gene discussed is IL22; the disease is graft versus host disease.